StockpollyBeta
Get App
Popularity #3,483
BNTC · NASDAQ · Biotechnology

Benitec Biopharma (BNTC)

Develops BB-301, a ddRNAi genetic medicine for OPMD dysphagia.

$9.90
vs last close−1.05 (−9.59%)

In millions of USD, except per-share figures

In millionsQ1 FY24Sep 2023Q2 FY24Dec 2023Q3 FY24Mar 2024Q4 FY24Jun 2024Q1 FY25Sep 2024Q2 FY25Dec 2024Q3 FY25Mar 2025Q4 FY25Jun 2025Q1 FY26Sep 2025Q2 FY26Dec 2025Q3 FY26Mar 2026Q4 FY26Jun 2026
Revenue000000010000
Cost of revenue000000000000
Gross profit000000000000
6746611151010131314
Research & development4534456436610
2222259136877
General & administrative2222259136877
Other expenses0000000−7000−2
Operating income−6−7−4−6−6−11−15−10−10−13−14−14
000111111222
Interest income000101100022
Interest expense0000−100−1−1−100
Other non-operating income000000000000
Income before tax−6−7−4−5−5−10−15−9−9−12−12−13
Net income from continuing operations−6−7−4−5−5−10−15−9−9−12−12−13
Net income−6−7−4−5−5−10−15−16−9−12−12−13
EPS, basic−$0.60−$0.54−$0.23−$0.53−$0.48−$0.33−$0.38−$0.39−$0.21−$0.26−$0.24−$0.27
EPS, diluted−$0.60−$0.54−$0.23−$0.53−$0.48−$0.33−$0.38−$0.39−$0.21−$0.26−$0.24−$0.27
Weighted average shares, basic91010101122393642464947
Weighted average shares, diluted91010101122393642464947
EBITDA−6−7−4−5−6−11−15−17−10−13−13−14
Depreciation & amortization000000000000
EBIT−6−7−4−5−6−11−15−17−10−13−14−14